Title : Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

Pub. Date : 2019 May

PMID : 30683630






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
2 Lorlatinib, a novel third-generation TKI, produced remarkable results from the first-in-man phase 1 trial: an overall response rate of 46% and 50% for previously treated ALK- and ROS1-positive patients, respectively. lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
3 CONCLUSION: This study is the first to report that lorlatinib is an important novel therapeutic option for Asian patients who have advanced NSCLC harboring ALK/ROS1 mutations whose disease progressed during treatment with first- and second-generation TKIs. lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens